We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Jazz Warned for Minimizing Risks of Schizophrenia Drug in Patient Promo
Jazz Warned for Minimizing Risks of Schizophrenia Drug in Patient Promo
September 28, 2012
Jazz Pharmaceuticals received an FDA warning letter for overstating the benefits and minimizing or omitting the risks of its schizophrenia drug FazaClo in a patient brochure.